Product image of Metoprololtartrat Omniapharm (Metoprolol Tartrate) supplied by GNH India

Metoprololtartrat Omniapharm

Active Ingredient:
Metoprolol Tartrate
Origin:
EU

Metoprololtartrat Omniapharm (Metoprolol Tartrate)

Metoprolol Tartrate, the active ingredient in Metoprololtartrat Omniapharm, is a beta blocker presented as an intravenous solution for cardiovascular use. It lowers blood pressure, relieves angina, and helps control heart rhythm in adult patients with relevant cardiac conditions.

GNH India supplies Metoprololtartrat Omniapharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards, meets EU regulatory requirements, and provides reliable global distribution with appropriate documentation to support import and clinical application.

Manufacturer / TM Owner

Recordati Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprololtartrat Omniapharm, a selective β1‑adrenergic blocker, is employed in several cardiovascular disease categories.

  • Hypertension: reduces systolic and diastolic blood pressure, improving overall vascular control.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest‑pain episodes.
  • Acute myocardial infarction: limits infarct size and reduces mortality when administered early.
  • Heart failure: improves left‑ventricular function and decreases hospitalization risk.
  • Cardiac arrhythmias: stabilizes heart rhythm by slowing conduction through the AV node.

How It Works

  • Metoprololtartrat Omniapharm acts as a selective β1‑adrenergic receptor antagonist. By binding to cardiac β1 receptors, it diminishes sympathetic stimulation, leading to reduced heart rate, decreased myocardial contractility, and lower cardiac output, which together lower arterial pressure and myocardial oxygen consumption.

Side Effects

Metoprololtartrat Omniapharm may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Fatigue: feeling of tiredness or reduced energy.
  • Dizziness or light‑headedness: due to lowered blood pressure.
  • Bradycardia: slower than normal heart rate.
  • Cold extremities: reduced peripheral circulation.

Serious or Rare Side Effects

  • Severe bronchospasm: can occur in patients with underlying airway disease.
  • Cardiogenic shock or severe heart block: life‑threatening reduction in cardiac output.

Precautions & Warnings

When prescribing Metoprololtartrat Omniapharm, clinicians should observe several safety measures.

  • Assess cardiac function: evaluate heart rate and blood pressure before initiation.
  • Adjust dose in renal impairment: monitor renal function and modify as needed.
  • Caution in asthma or COPD: β‑blockade may precipitate bronchospasm.
  • Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension.
  • Monitor for signs of heart‑failure exacerbation: watch for edema or dyspnea.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Avoid Interactions

Metoprololtartrat Omniapharm can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

  • Combined use with non‑selective β‑blockers: may cause excessive bradycardia.
  • Concomitant calcium channel blockers (verapamil, diltiazem): risk of severe AV block.
  • Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase plasma metoprolol levels.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: may mask hypoglycemia symptoms.
  • NSAIDs (e.g., ibuprofen): can reduce antihypertensive effect.
  • Diuretics: may enhance hypotensive response.

Frequently Asked Questions

Metoprololtartrat Omniapharm is used to manage hypertension, relieve angina pectoris, treat acute myocardial infarction, support heart‑failure therapy, and control certain cardiac arrhythmias by targeting the β1‑adrenergic receptors in the heart.

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors on cardiac cells, reducing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, decreased contractile force, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The dose of Metoprololtartrat Omniapharm is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments may be required for renal function, age, or concomitant therapies.

Safety data for Metoprololtartrat Omniapharm in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprololtartrat Omniapharm is a selective β1‑blocker, offering cardiac‑focused effects with fewer respiratory side effects compared with non‑selective agents. Its intravenous formulation allows rapid onset, which can be advantageous in acute settings such as myocardial infarction or severe hypertension.

Store Metoprololtartrat Omniapharm at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Metoprololtartrat Omniapharm is administered intravenously by a qualified healthcare professional. The infusion rate and concentration are set according to the clinical protocol and the patient's cardiovascular status.

Serious risks include severe bradycardia, heart block, cardiogenic shock, and bronchospasm in patients with underlying airway disease. Prompt recognition and appropriate medical intervention are essential if these events occur.

Patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe sinus bradycardia, second‑ or third‑degree AV block without a pacemaker, or uncontrolled asthma/COPD should avoid using Metoprololtartrat Omniapharm unless specifically directed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Tartrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT